Management of life-threatening hemorrhages and unsafe interventions in nonhemophiliac children by recombinant factor VIIa.
The literature on the use of recombinant factor VIIa (rFVIIa), which was initially used in hemophiliac patients with inhibitors, for hemorrhages that cannot be managed with conventional methods or operations that cannot be performed safely is increasingly growing. This study presents a group of nonhemophiliac patients with hemorrhagic problems or hemorrhage risk for some interventions that were successfully resolved with the use of rFVIIa. The patient group was composed of 20 patients with different disorders resulting in similar results as hemorrhage or hemorrhage risk. Most of the patients were diagnosed with liver disorders primary or secondary to other diseases. The remaining cases were patients with leukemia, sepsis, intracranial hemorrhage, and burn. Some of the patients had multiple problems like a patient with liver disorder and intracranial hemorrhage or a leukemia patient with sepsis and disseminated intravascular coagulation. rFVIIa had been administered to the patients at dosages between 70 and 150 microg/kg up to 6 doses with 2-hour to 3-hour intervals. All the patients had benefited from the use of rFVIIa even though some of them died because of primary disease. This study shows that rFVIIa can be safely used in high-risk patients with a history of recurrent hemorrhage, for whom no improvement can be achieved in the hemostasis tests.
Leblebisatan
Göksel
G
Department of Pediatric Hematology, Cukurova University Medical Faculty, Adana, Turkey. gokselleb@yahoo.com
Sasmaz
Ilgen
I
Antmen
Bulent
B
Yildizdas
Dincer
D
Kilinc
Yurdanur
Y
D000208:Acute Disease; D000293:Adolescent; D002056:Burns / Q000097:blood / Q000150:complications; D002648:Child; D002675:Child, Preschool; D003029:Coagulants / Q000627:therapeutic use*; D016638:Critical Illness; D015942:Factor VIIa / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000097:blood / Q000150:complications*; D008107:Liver Diseases / Q000097:blood / Q000150:complications; D008297:Male; D056687:Off-Label Use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012189:Retrospective Studies; D018805:Sepsis / Q000097:blood / Q000150:complications; D016896:Treatment Outcome
D003029:Coagulants; D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa